IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Schaller, Heinz, et al.

Serial No.: 09/383,978

Filed: August 26, 1999

For: METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS GENES IN HEPATOCYTES USING HEPADNAVIRAL

VECTORS

Attorney Docket No.: BBI-102CP

Assistant Commissioner for Patents Washington, D.C. 20231

Group Art Unit: 1632

Examiner:

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

3-28-00

Date of Signature and of Mail Deposit

Bv:

Catherine J. Kara, Ph.D.

Reg. No. 41,106

Attorney for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their attorney have become aware of the following publications and information, cited in an International Search Report mailed February 15, 2000 during the prosecution of PCT/US99/19452 which corresponds to the above referenced application. In accordance with 37 CFR §1.97(b)(3), Applicants hereby submit these publications for the Examiner's consideration. These publications are cited on the enclosed PTO Form 1449, and a copy of the Report and each publication cited thereon are enclosed as well.

Serial Number: 09/383,5 Page -2-Group Art Unit: 1632

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed per se as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

The undersigned hereby certifies that each item contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

> Respectfully submitted, LAHIVE & COCKFIELD, LLP

Catherine J. Kara, Ph.D. Registration No. 41,106

Attorney for Applicants

28 State Street Boston, MA 02109 (617) 227-7400

Date: March 28, 2000

GAD/EAH/CJK/JLE/mlh

Enclosures

	APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80 LIST OF PUBLICATIONS			MERCE ENT AND TRADEMARK OFFICE ADDITO ANT	ATTY DOCKET NO BBI-102CP APPLICANT		Sheet 1 of 1 SERIAL NO. 09/383,978			
2,0,		Use several shee			Schaller, Heinz et al. FILING DATE GROUP					
					August 26, 199	9	1632			
			U.	S. PATENT DOC	JMENTS		_			
EXAMINER INITIAL	B1	DOCUMENT NUMBER	DATE		KAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIA		
	-	5,981,274	11/99	Tyrrell et al.	· · · · · · · · · · · · · · · · · · ·	435	320.1			
			FORE	EIGN PATENT DO	CUMENTS					
	DOCUMENT NUMBER		DATE	c	CLASS	SUBCLASS	TRANSLATION YES N			
	В2	WO 98/09524	03/98	PCT				YES		
			<u> </u>							
·				g Author, Title, Da						
	В3	Gutterman, Jo USA 91:1198	ordan U. " -1205 (19)	Cytokine therapeu 94)	itics: Lessons fror	m interferon	a," Proc. Na	tl. Acad	. Sc	
	B4	Konishi, Kaor 18/interferon-	ishi, Kaori et al. "A simple and sensitive bioassay for the detection of human interleukinterferon-γ-inducing factor using human myelomonocytic KG-1 cells," <i>J. Immunologic</i>							
	B5	Methods 209(2):187-91 (1997) Protzer, Ulrike et al. "Interferon gene transfer by hepatitis B virus vector efficient wild-type virus infection," Proc. Natl. Acad. Sci. USA 96(19):10818-23 (1999)						suppress	ses	
			· · · · · · · · · · · · · · · · · · ·	,		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(1000)			
			- W.	*****			· · · · · ·			
										
		<u> </u>	*******			_				
	\perp					<u> </u>		···		
	_		<u></u>				·			
	\downarrow									
xaminer				T r) Date Considered	7/E				

	LIST OF PUBLICATIONS (Use several shee)					ATTY DOCKET NO BBI-102CP APPLICANT Schaller, Heinz et al. FILING DATE August 26, 1999		Sheet 1 of 1 SERIAL NO. 09/383,978 GROUP 1632		
10										
A OFE	T			U.	S. PATENT DOCI					
*	EXAMINER INITIAL		DOCUMENT NUMBER	DATE		IAME	CLASS	SUBCLASS		DATE
	TIL	B1	5,981,274	11/99	Tyrrell et al. 43		435	320.1	IF APPR	OPRIAT
L				500	TION DATENT DO			<u> </u>		
Γ			DOCUMENT NUMBER		IGN PATENT DO					
L			DOCOMENT NOMBER	DATE	٥	DUNTRY	CLASS	SUBCLASS	TRANSLATIO YES 1	
	M	82	WO 98/09524	03/98	PCT			1	723	Γ
	iv f	B5	18/interferon- Methods 209(Protzer, Ulrike	γ-inducing 2):187-91 e et al. "In	g factor using hum (1997) terferon gene tran	ve bioassay for the an myelomonocyti sfer by hepatitis B I. Sci. USA 96(19)	ic KG-1 cel	ls," J. Immun	ological	•
	_	-								

					·					
									· · · · · · · · · · · · · · · · · · ·	
	xamiyêr					ate Considered,				

		·				•••.	0.	-1.4.4.				
1	FACSIM	ILE OF FORM PTO-1449		DEPARTMENT OF	ATTY DOCKET NO	 	She SERIAL NO.	et 1 of 1				
REV 7-80			PAT	ENT AND TRADEMARK OFFICE	BBI-102CP				09/383,978 # 4			
LIS		PUBLICATIONS (Use several sheet)			APPLICANT	4 -1						
		·	7.5 II 11000	33aiy)	Schaller, Heinz et al.							
					August 26, 199	99	1632					
			U.	S. PATENT DOC	UMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME CLASS		SUBCLASS		FILING DATE			
				<u> </u>				IF APPROPRIATE				
							 					
			FOR	EIGN PATENT DO	CUMENTS		<u>. •</u>	<u>. </u>				
		DOCUMENT NUMBER	DATE					TRANSLATION				
W/	A1	WO 90/02176	03/90	PCT	-/ -	(E)	 	YES	NO			
Sol	A2	EP 421 635	04/91	EP	- (FEB 2 8 2	- [일			 			
The	A3	WO 95/06745	03/95	PCT	E. E.	38	†	Abstr.				
Sull	A4	WO 96/35797	11/96	PCT	TRAD!			yes				
5n/	A5	WO 98/11916	03/98	PCT								
		OTHERS	(including	g Author, Title, Da	to Portinant Base							
20	A6	Chaisomchit,	S. et al., "	Development of re	eplicative and nor	replicative h	nepatitis B vi	rus vecto	ors "			
21/2	A7	Gene Ther. 4	Chaisomchit, S. et al., "Development of replicative and nonreplicative hepatitis B virus vectors," Gene Ther. 4:1330-1340 (1997)									
mes	A8	Thesis, Unive	Chiang, P.W., "Characterizing cis elements which are essential for the HBV replication," (1992) Thesis, University of Heidelberg									
900X		nepatitis B vir	Horwich, A.L. et al., "Synthesis of hepadnavirus particles that contain replication-defective duck hepatitis B virus genomes in cultured HuH7 cells," <i>J. Virol.</i> 64:642-650 (1990)									
SIL	A9	Horwich, A.L.	et al., "Int r. <i>Topics ii</i>	nerited hepatic enz n Microbiology and	yme defects as o	candidates fo	or liver-direc	ted gene	<u>;</u>			
and	A10	Löser, Peter e	et al., "Eva	luation of HBV Pro	omoters for Use in	n Hepatic G	ene Therapy	ı," Biol. C	Chem.			
-	A11		Hoppe-Seyler 377:187-193 (1996) Summers, Jesse et al., "Hepadnavirus Envelope Proteins Regulate Covalently Closed Circular									
Sp	A12	UNA Amplifica	ation," J. V	/irology 64(6):2819	9-2824 (1990)							
Sul		hepatitis B vir	us," <i>J Viro</i>	o experimental infe d. 58(1):17-25 (198	ection of primary (36)	duck nepato	cyte culture:	s with du	ck			
<i></i>	<u>-</u> -				·							
ŀ		ŀ										
												
	\dashv							· · · ·				
			•									
					 							
	\downarrow											
Examiner		/ ~ ~ ~ ·	//	, ,	ate Considered	/ -						
*EYA1***		ras / Ku	A.	<u>'</u>	5/18/	50						
*EXAMINE	-KY	f Initial if refe if not in con	rence tonsid formance ar	dered, whether or not on the considered. Inc.	citation is in conforma lude copy of this form	nce with MPEF with next com	P 609; Draw line munication to a	e through o	citation			